BJH - volume 8, issue 2, march 2017
M-C. Vekemans MD, K. Beel MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, G. Bries MD, PhD, H. Demuynck MD, B. De Prijck MD, H. De Samblanx MD, A. Deweweire MD, K. Fostier MD, A. Kentos MD, P. Mineur MD, M. Vaes MD, I. Vande Broek MD, PhD, A. Vande Velde MD, J. Van Droogenbroeck MD, PhD, P. Vlummens MD, K.L. Wu MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD, C. Doyen MD, PhD, On behalf of the Multiple Myeloma Study Group of the Belgian Haematology Society (BHS)
The prognosis for multiple myeloma patients has improved substantially over the past decade with the development of more effective chemotherapeutic agents and regimens that possess a high level of anti-tumour activity. However, nearly all multiple myeloma patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed disease remains a critical aspect of multiple myeloma care and an important area of ongoing research. This manuscript from the Belgian Haematology Society multiple myeloma subgroup provides some recommendations on the management of relapsed disease.
(BELG J HEMATOL 2017;8(2):53–65)
Read moreBJH - volume 8, issue Abstract Book BHS, february 2017
B. Malfait MD, J. Braakman , L. de Vos , B. Bailly MD, I. Vande Broek MD, PhD, S. Meers MD, PhD, D. Dierickx MD, PhD
BJH - volume 7, issue Abstract Book BHS, january 2016
I. De haes , D. Schepens , I. Vande Broek MD, PhD
BJH - volume 5, issue 4, december 2014
M-C. Vekemans MD, K. Beel MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, G. Bries MD, PhD, V. Delrieu MD, H. Demuynck MD, B. De Prijck MD, H. De Samblanx MD, A. Deweweire MD, A. Kentos MD, P. Mineur MD, F. Offner MD, PhD, I. Vande Broek MD, PhD, A. Vande Velde MD, J. Van Droogenbroeck MD, PhD, KL. Wu MD, PhD, C. Doyen MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD
With the introduction of immunomodulatory drugs and proteasome inhibitors, major improvements have been achieved in the treatment and prognosis of multiple myeloma. Different treatment combinations are now in use and innovative therapies are being developed. This rapidly changing therapeutic landscape calls for an update on the Belgian myeloma guidelines, published in 2010.1 Based on an extensive review of the recent literature, the myeloma study group of the Belgian Hematology Society has revised the consensus recommendations on myeloma care, to be used by haematologists as a reference for daily practice. When applicable, comments with regards to the Belgian reimbursement modalities are included. The full text with appendices can be downloaded from the Belgian Hematology Society website (www.bhs.be) and from the Belgium Journal of Hematology website (www.ariez.com).
(BELG J HEMATOL 2014;5(4):125–36)
Read moreBJH - volume 5, issue Abstract Book BHS, january 2014
J. Caers MD, PhD, M-C. Vekemans MD, I. Vande Broek MD, PhD, V. Maertens MD, P.H. Mineur , G. Bries MD, PhD, E. Vandeneste , G. Vanstraelen , K. Beel MD, PhD, F. Leleu , H. Demuynck MD, C. Scheurmans , A. Van de Velde MD, W. Schroyens MD, PhD, K.L. Wu MD, PhD, N. Meuleman MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD, C. Doyen MD, PhD
BJH - 2013, issue BHS Abstractbook, january 2013
J. Caers MD, PhD, M-C. Vekemans MD, I. Vande Broek MD, PhD, P.H. Mineur , K. Beel MD, PhD, V. Maertens MD, C. Schuermans MD, F. Leleu , G. Vanstraelen , H. Demuynck MD, W. Schroyens MD, PhD, E. Van den Neste MD, PhD, G. Bries MD, PhD, A. Van de Velde MD, M. Delforge MD, PhD, C. Doyen MD, PhD
Top
